Platelet aggregation in focal cerebral ischemia -a clinical study

Area of Science:

• Neurology
• Hematology
• Cardiovascular Medicine

Background:

• Platelet aggregation plays a crucial role in thrombotic events like transient ischemic attacks (TIAs) and stroke.
• Understanding the prevalence of pathological platelet aggregation post-event is vital for guiding prophylactic strategies.

Purpose of the Study:

• To investigate the frequency of pathological platelet aggregation in patients following TIAs and completed strokes.
• To evaluate the efficacy and safety of antiplatelet agents (acetylsalicylic acid and dipyridamole) in normalizing platelet aggregation and preventing recurrent cerebrovascular events.

Main Methods:

• Prospective study of 35 patients with TIAs and 54 patients with completed stroke.
• Assessment of platelet aggregation levels 4 weeks after the latest TIA or cerebral infarction.
• In vitro testing of acetylsalicylic acid and dipyridamole on pathological platelet aggregation.
• Clinical follow-up to monitor recurrent TIAs and stroke outcomes during antiplatelet therapy.

Main Results:

• 74% of TIA patients exhibited pathological platelet aggregation 4 weeks post-event.
• 37% of stroke patients showed pathological platelet aggregation 4 weeks post-infarction.
• Acetylsalicylic acid and dipyridamole normalized in vitro platelet aggregation with low side effect frequency.
• Antiplatelet treatment halted further TIAs in 17/19 patients and led to remission in 14/14 stroke patients.

Conclusions:

• Pathological platelet aggregation is a frequent finding after TIAs and strokes, often necessitating prophylactic treatment.
• Antiplatelet therapy with acetylsalicylic acid and dipyridamole is effective in normalizing platelet aggregation and preventing recurrent cerebrovascular events.
• Antiplatelet agents show a trend towards more favorable outcomes in stroke patients compared to anticoagulants.